Quantcast

Latest Idiopathic thrombocytopenic purpura Stories

2008-08-22 15:00:51

Amgen Inc. (NASDAQ: AMGN) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nplate(TM) (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP). Nplate, the first FDA-approved peptibody protein, works by raising and sustaining platelet counts, representing a novel approach for the long-term treatment of...

2008-07-17 12:01:18

Symphogen and Biovitrum have announced the recruitment of the first patient into a Phase II clinical trial, initiated in June 2008 to evaluate the safety and efficacy, and explore the dose range of Sym001 in idiopathic thrombocytopenic purpura patients. Up to 55 RhD-positive adult non-splenectomized patients with idiopathic thrombocytopenic purpura (ITP) will be enrolled in this first exploratory open label safety, efficacy and dose-finding trial. The study objective is to evaluate the...

2008-07-16 09:01:20

COPENHAGEN, Denmark and STOCKHOLM, Sweden- July 16, 2008. Symphogen A/S and Biovitrum AB (publ) (STO: BVT) today announced the recruitment of the first patient into a Phase II clinical trial, initiated in June, to evaluate the safety and efficacy, and explore the dose range of Sym001 in Idiopathic Thrombocytopenic Purpura (ITP) patients. Sym001 is a recombinant, polyclonal anti-Rhesus D antibody product candidate. Symphogen and Biovitrum are jointly developing Sym001 under a...

2008-06-20 18:00:39

PHILADELPHIA, Pa. June 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura, as they require more time to review the application. The Prescription Drug User Fee action date has been extended to September 19, 2008. On May 30, the Oncology Drugs Advisory...

2008-06-20 18:00:07

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that the U.S. Food and Drug Administration has extended the priority review period for GlaxoSmithKline's (GSK) New Drug Application (NDA) for PROMACTA(R) (eltrombopag) for the short-term treatment of chronic idiopathic thrombocytopenic purpura (ITP). The Prescription Drug User Fee action date has been extended to September 19, 2008. GSK submitted an NDA for PROMACTA in December 2007. In March 2008, the FDA granted the drug...

2008-06-16 09:01:17

Amgen has announced new positive data from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura, a chronic and serious autoimmune disorder characterized by low platelet counts in the blood. The results continue to show that romiplostim increased and sustained platelet counts with extended treatment, and reduced the need for concurrent and rescue immune thrombocytopenic purpura (ITP)...

2008-06-15 06:00:22

Amgen Inc. (NASDAQ: AMGN) today announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts in the blood. The updated results continue to show that romiplostim increased and sustained platelet counts with extended treatment, and reduced the need for concurrent and rescue ITP...

2007-11-28 18:00:00

PHILADELPHIA, Nov. 28 /PRNewswire-USNewswire/ -- Data from Phase II studies published today in the New England Journal of Medicine (NEJM) report that GlaxoSmithKline's (GSK) investigational compound PROMACTA (TM) (eltrombopag) significantly raised platelet levels in patients with thrombocytopenia (low number of platelets in the bloodstream). The studies were conducted in chronic hepatitis C (HCV) (See Note 1)(where thrombocytopenia complicates disease treatment) and chronic idiopathic...

2007-11-28 15:00:37

A U.S.-led international study has discovered a potential new treatment for chronic immune thrombocytopenic purpura, an autoimmune disease. Researchers at New York-Presbyterian Hospital-Weill Cornell Medical Center said there are an estimated 50,000 to 100,000 people in the U.S. diagnosed with ITP, a disease that reduces the number of blood platelets, causing bruises, nosebleeds and possibly life-threatening brain hemorrhages. In the study, the scientists discovered an investigational...

2007-11-11 03:00:07

By Boren, Todd Reyes, Carlos; Montenegro, Raul; Raimer, Karen Abstract Evan's syndrome is a rare hematological condition defined as immune thrombocytopenic purpura and hemolytic anemia. We describe herein a case of Evan's syndrome diagnosed in a term pregnancy that was refractory to primary therapeutic options. We also describe current treatment options in pregnancy and briefly discuss the pathophysiology of Evan's syndrome and perinatal outcome. Keywords: Pregnancy, Evan's syndrome,...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related